ESG Performance

Collage of multiple pictures with two men, a building solar installation and a Pride Alliance event

We're continuing to successfully deliver against our ESG commitments, with examples including:

Advancing clinical trials investigating a twice-yearly injectable to prevent HIV transmission.
Expanding our efforts to increase access and remove barriers to care. Our voluntary licensing programs provided access to HIV treatments based on Gilead’s innovation to more than 20 million people in low- and middle-income countries. We're highly ranked among philanthropic funders of HIV-related programs by Funders Concerned About AIDS, and we donated nearly $300 million in 2023 to multiple programs and partner efforts aligned with our mission.

Further reducing the median delivery time for our industry-leading CAR T-cell therapy. Every day matters for patients receiving this treatment as their disease can progress rapidly.
Making significant progress toward ambitious climate targets, which include a commitment to a 46% reduction in greenhouse gas emissions by 2030 and to achieve water neutrality in water-stressed regions by 2030.

Impact by the Numbers

30M

People gained access to HIV, viral hepatitis and COVID-19 therapies through voluntary licensing in 2023

758K

Educational touchpoints with healthcare providers in 2023

17.9M

HIV and viral hepatitis tests conducted through FOCUS program since 2010

20

Diversity in clinical trial grants funded since 2022

$270M

Donated globally in 2023

$515M

Spent with diverse suppliers in 2023

External Ratings and Rankings

In 2023, Gilead's Climate Change score improved to A-, representing leadership in climate disclosure, a grade granted by CDP, a nonprofit that runs a global environmental disclosure system.

Gilead ranked 16th in the 2024 Access to Medicine Index, performing well in access strategies for its products on the market and engaging widely in non-exclusive voluntary licensing.

We were included on the Dow Jones Sustainability World Index as one of the most sustainable pharmaceutical companies for the fourth consecutive year in 2024.

in 2025, Gilead was once again ranked in the top five of America's Most Just Companies in biopharma, reflecting our commitment to operating responsibly.